PF-05089771

DB14856InvestigationalSmall molecule

PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).

Mechanism: Pharmacologically active on Sodium channel protein type 9 subunit alpha
Curator reviewed
Formula / weight: C₁₈H₁₂Cl₂FN₅O₃S₂ · 500.34 g/mol (avg)
Code names: PF-05089771

Resolves to

Compound

UNII25U4N985O2CAS1235403-62-9ChEMBLCHEMBL2325014

Structure

InChIKeyZYSCOUXLBXGGIM-UHFFFAOYSA-NSMILESNC1=C(C=NN1)C1=CC(Cl)=CC=C1OC1=CC(F)=C(C=C1Cl)S(=O)(=O)NC1=CSC=N1

Targets

Q15858SCN9AQ96S37SLC22A12

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-05089771, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account